SCHEMBL7501599

SCHEMBL7501599

COc1ccc(-c2ccc(-c3csc4ccccc34)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.53
ERN1 O75460 2/20 0.48
MAPT P10636 3/20 0.47
TP53 P04637 2/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
MAPK1 P28482 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
HSD17B10 Q99714 1/20 0.47
ABL1 P00519 1/20 0.46
ABCB1 P08183 1/20 0.46
BCR P11274 1/20 0.46
PTGER2 P43116 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368387 0.98 MAOB (0.54) MAOBERN1MAPTTP53NPC1
SCHEMBL23555986 0.86 ERN1 (0.54) MAOBERN1MAPTSMN1; SMN2ALDH1A1
SCHEMBL5766614 0.82 ERN1 (0.51) MAOBERN1MAPTNPC1RAB9A
SCHEMBL5815037 0.81 MAOB (0.44) MAOBMAPTNPC1RAB9ASMN1; SMN2
SCHEMBL7384280 0.79 MAOB (0.52) MAOBERN1MAPTTP53NPC1
SCHEMBL8341333 0.79 PIN1 (0.51) MAOBERN1MAPTTP53NPC1
SCHEMBL31092063 0.78 CYP2A6 (0.52) MAOBERN1MAPTALDH1A1HDAC4
SCHEMBL5848721 0.78 CYP2A6 (0.52) MAOBERN1MAPTALDH1A1HDAC4
SCHEMBL6283755 0.78 MAPT (0.51) MAOBMAPTTP53SMN1; SMN2ALDH1A1
SCHEMBL28046144 0.78 ERN1 (0.43) MAOBERN1BACE1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1077967-B1 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-12-04 EP disclosed
EP-1077966-B1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA WYETH CORP (US) 2002-11-20 EP disclosed
US-6391897-B2 (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID, FOR EXAMPLE; INHIBIT PROTEIN-TYROSINE PHOSPHATASES (PTPASES) AMERICAN HOME PRODUCTS CORPORATION 2002-05-21 US disclosed
US-6369072-B2 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS CORPORATION 2002-04-09 US disclosed
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia WYETH 2001-12-20 US disclosed
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia AMERICAN HOME PRODUCTS 2001-11-15 US disclosed
US-6310081-B1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS AMERICAN HOME PRODUCTS CORPORATION 2001-10-30 US disclosed
US-6232322-B1 SUCH AS (4'-BENZOFURAN-3-YL-BIPHENYL-4-YLOXY)-ACETIC ACID OR SALT AMERICAN HOME PRODUCTS CORPORATION 2001-05-15 US disclosed
US-6221902-B1 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS AMERICAN HOME PRODUCTS CORPORATION 2001-04-24 US disclosed
EP-1077966-A1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
EP-1077967-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 2001-02-28 EP disclosed
WO-1999058518-A2 BIPHENYL OXO-ACETIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed
WO-1999058520-A1 BIPHENYL SULFONYL ARYL CARBOXYLIC ACIDS USEFUL IN THE TREATMENT OF INSULIN RESISTANCE AND HYPERGLYCEMIA AMERICAN HOME PRODUCTS CORPORATION (US) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053785-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP MAOB 540/4885ERN1 3476/4885MAPT 4080/4885
US-20010041715-A1 Biphenyl oxo-acetic acids useful in the treatment of insulin resistance and hyperglycemia GPR119, INSR, IAPP MAOB 540/4885ERN1 3476/4885MAPT 4080/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.